atezolizumab,pembrolizumab
Roche,merck
['renal,(-adrenal)']
two renal cancer adjuvant studies were presented today at #esmo2022 with disappointing results. different populations and drugs, short follow-ups or factors that we still do not know may cause these discordant results 
Medical oncologist. Clinical researcher focused in GU tumors. Director Institute of Oncology. Associate Professor UCM. Hospital Clinico San Carlos Madrid, Spain